JLE

Sang Thrombose Vaisseaux

MENU

The gut microbiota and cardiovascular diseases Volume 30, issue 1, January-February 2018

Figures


  • Figure 1
Authors
1 APHP, Hôpital Cochin, Service de cardiologie, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
2 APHP, Hôpital Louis-Mourier, Université Paris Diderot, Service de gastro-entérologie, 178, rue des Renouillers, 92700 Colombes, France
3 APHP, Hôpital Saint-Antoine, Service de gastro-entérologie et nutrition, 184, rue du Faubourg Saint-Antoine, 75012 Paris, France
* Tirés à part

The gut microbiota, known for its interaction with the host, revealed an important role in metabolic and cardiovascular diseases. The change in structure and function of the gut microbiota, known as dysbiosis, is correlated to the pathophysiology of these diseases. As the urge to understand more precisely the pathophysiology in order to develop effective therapeutics, new metabolites of the gut microbiota were discovered: some are considered as deleterious (trimethylamin N-oxide [TMAO]) and others as beneficial (bile acids, short chain fatty acids). The current hypothesis of low grade chronic inflammation might be explained by these metabolites. The purpose of this mini-review is to highlight the complex interaction between the host and the gut microbiota, its implication in cardiovascular diseases and the therapeutic strategies that can arise.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License